USTR has today launched an Out-of-Cycle Review for India, per this year’s Special 301 Report. USTR is accepting public comments until October 31st. (Interesting to note that it is only a two week window. For the last Review it was 3 weeks for public comments.)
Read the announcement here
In the 2014 Special 301 Report, the Office of the United States Trade Representative (USTR) announced that, in order to assess progress on engagement with the Government of India on intellectual property rights (IPR) issues, an Out-of-Cycle Review (OCR) would be conducted for India. USTR requests written submissions from the public concerning information, views, acts, policies, or practices relevant to evaluating the Government of India’s engagement on IPR issues of concern, in particular those identified in the 2014 Special 301 Report. The 2014 Special 301 Report is available at www.ustr.gov.
Friday, October 31, 2014—Deadline for the public, except foreign governments, to submit written comments.
Friday, November 7, 2014—Deadline for foreign governments to submit written comments.
India would like to thank the chair for initiating the discussion on non-violation and other situation complaints under the TRIPS Agreement today. India associates itself with the statements made by Venezuela and Brazil which raise fundamental concerns on the applicability of non-violation complaints under the TRIPS Agreement.
Obama Has Been Fighting Doctors Without Borders For Years
Source: Huffington Post
30 Oct 2014
For years, President Barack Obama and his administration have been fighting Doctors Without Borders over drug costs. (Photo by Darren Hauck/Getty Images) | Darren Hauck via Getty Images
WASHINGTON — It’s a little unusual to see the Obama administration singing the praises of Doctors Without Borders, the Nobel Peace Prize-winning nonprofit that is shipping doctors, drugs and supplies to West Africa to combat the Ebola outbreak.
When President Barack Obama lauded the “incredible heroism” of American doctors who travel to countries such as Sierra Leone to do “God’s work” and “keep us safe,” on Tuesday, he was celebrating a community packed with Doctors Without Borders volunteers. United Nations Ambassador Samantha Power has been more explicit, using the acronym for the international group’s French name, Medicines Sans Frontiers, in speeches and on Twitter.
“MSF … are already leading the charge,” Power told the U.N. Security Council in September, before conveying the harrowing story of one MSF staffer’s experience fighting Ebola in Monrovia.
Source: Economic Times
30 Oct 2014
Cipla, India’s fifth largest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug Onbrez.
NEW DELHI: Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug Onbrez and launched its generic version of indacaterol at a fifth of the price, triggering another confrontation between an Indian generic company and a foreign innovator firm. The domestic drugmaker asked the Department of Industrial Policy & Promotion to cancel the patents on the ground that the Swiss company has held them for six years without making the medicine locally or importing it in the quantity that’s required.
Source: Business Line
MUMBAI, OCT. 26:
Close to 10 years after the Indian Patents Act was amended in January 2005, discussions around intellectual property are on the boil again.
Last week, the Government set up a think tank to draft a national policy on intellectual property rights (IPR), and have a coordinated IP approach across various Government departments. Continue reading
Source: Business Line
NEW DELHI, OCT 24:
The Government has constituted an Intellectual Property Rights (IPR) think-tank to help draft a new National IPR Policy and to advice it on issues related to intellectual property.
The think-tank, headed by Justice Prabha Sridevan, will highlight anomalies in the present IPR legislations and advice the Department of Industrial Policy and Promotion (DIPP) on possible solutions, according to an official release. Continue reading
Source: Times of India
NEW DELHI: The man who has been appointed the chief economic adviser to the government of India, Arvind Subramanian, was until recently urging the US to initiate disputes against India before the World Trade Organization.
He also sought changes in provisions within Indian patent law aimed at preventing frivolous patenting and preventing pharmaceutical companies from getting extensions on patents by tweaking existing drugs and passing them off as innovations. Continue reading
Source: Business Line
Thanks to the India-US Intellectual Property Working Group. Here’s how — and why this is bad news for India’s poor
Prime Minister Narendra Modi’s first official visit to the US included several meetings with industry representatives and a meeting with President Barack Obama. In the US-India joint statement that was issued on September 30, a brief passage under “Economic Growth” stated that the leaders had “committed to establish an annual high-level Intellectual Property Working Group with appropriate decision-making and technical-level meetings”. Continue reading
Posted in access to medicines, BRICS, Compulsory Licensing, Drug Pricing, FDI, Generic drug, Intellectual Property, IP Rights, IPR policy, Patent examination system, Patent Term Extension, R&D, US pressure on India, USTR 301 report, WTO
Tagged India-US Intellectual Property Working Group, Pharmaceutical patents, US Chamber of Commerce